Insmed Incorporated
INSM
Ранг среди акций
#1109
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Цена акции
$95.88
Рыночная капитализация
$20.94B
Изменение (1 день)
0.61%
Изменение (1 год)
-42.90%
Страна
US
Торговля Insmed Incorporated (INSM)
Категория
Healthcare
История дроблений акций Insmed Incorporated (INSM)
Акции Insmed Incorporated (символ: INSM) прошли через 2 дроблений.
Последнее дробление произошло Mar 03, 2011.
Одна акция INSM, купленная до Jul 31, 2000, сейчас соответствует 0.025 акциям INSM.
Последнее дробление произошло Mar 03, 2011.
Одна акция INSM, купленная до Jul 31, 2000, сейчас соответствует 0.025 акциям INSM.
Список дроблений акций
| Год | Дробление | Коэффициент | Суммарный коэффициент |
|---|---|---|---|
| 2011-03-03 | 1:10 | x0.1 | x0.025 |
| 2000-07-31 | 1:4 | x0.25 | x0.25 |
Дробления акций аналогичных компаний или конкурентов
| Компания | Количество дроблений акций | Суммарный коэффициент | Страна |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
